Rain Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Rain Therapeutics Inc. will be represented by CEO Avanish Vellanki at the Goldman Sachs 42nd Annual Global Healthcare Conference from June 8-11, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rain Therapeutics Inc. will be represented by CEO Avanish Vellanki at the Goldman Sachs 42nd Annual Global Healthcare Conference from June 8-11, 2021. He will present a corporate overview and engage in one-on-one investor meetings on June 10 at 5:30 p.m. ET. The presentation will be accessible via a webcast link and on the company's website. A replay will be available for 30 days following the event. Rain focuses on precision oncology, with its lead product RAIN-32 targeting MDM2 in various cancers.
Details
News Market Reaction – RAIN
The recorded move for RAIN in the trading session of this news was +1.50%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present a corporate overview and participate in one-on-one investor meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference taking place virtually from June 8-11, 2021.
Presentation details can be found below:
Date: Thursday, June 10, 2021
Time: 5:30 p.m. ET
Location: Webcast Link – or at the company’s website (click here)
A replay of the presentation will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. For more information, visit www.rainthera.com.
Media Contact:
Grace Fotiades
LifeSci Communications
+1.646.876.5026
gfotiades@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.